Citigroup assumed coverage on shares of Unity Biotechnology (NASDAQ:UBX) in a research report released on Tuesday, May 29th, Marketbeat.com reports. The firm issued a buy rating and a $32.00 price objective on the stock.
UBX has been the subject of several other research reports. Morgan Stanley initiated coverage on Unity Biotechnology in a report on Tuesday, May 29th. They issued an overweight rating and a $25.00 price objective for the company. Goldman Sachs Group initiated coverage on Unity Biotechnology in a research note on Tuesday, May 29th. They issued a neutral rating and a $17.00 price target on the stock.
Unity Biotechnology traded up $0.19, reaching $14.98, during trading hours on Tuesday, Marketbeat reports. 289 shares of the stock were exchanged, compared to its average volume of 155,846. Unity Biotechnology has a twelve month low of $12.75 and a twelve month high of $20.48.
Unity Biotechnology, Inc, a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases.
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.